Wednesday, November 11, 2026

OpenAI Develops 'Sweetpea' to Compete with Apple's AirPods Dominance in Wearables Market

OpenAI’s ‘Sweetpea’ Wearable Aims to Challenge Apple’s AirPods.

LM Salvado

January 14, 2026

OpenAI Develops 'Sweetpea' to Compete with Apple's AirPods Dominance in Wearables Market
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI's 'Sweetpea' Wearable Aims to Challenge Apple's AirPods

According to The Decoder, OpenAI is reportedly developing a new audio wearable device codenamed "Sweetpea," which aims to compete directly with Apple's popular AirPods. If the leak is accurate, the device could be a significant entry into the wearables market, challenging Apple's dominance and potentially reshaping the landscape of smart audio accessories.

The alleged development of "Sweetpea" underscores the growing interest in integrating advanced AI capabilities into everyday wearable tech. As tech giants like Apple continue to dominate the market, the emergence of a new player with the backing of OpenAI could bring fresh innovations and competition. This move also highlights the increasing role of AI in consumer electronics, where seamless integration and user experience are paramount.

According to The Decoder, "Sweetpea" will feature an oval metal housing with two capsule-shaped components worn behind the ear. The device is said to be equipped with a 2nm chip, with Samsung Exynos being the leading contender for the processor. Additionally, the device will include a separate chip that enables control via Siri, Apple's voice assistant. The material costs for "Sweetpea" are reportedly comparable to those of smartphones, indicating a high-end product aimed at discerning consumers.

The involvement of renowned designer Jony Ive, known for his work on iconic Apple products, adds another layer of intrigue to the project. If the device launches as expected in September, OpenAI aims to sell between 40 to 50 million units in its first year. This ambitious target suggests a strong belief in the product's potential to capture a significant share of the market.

Production of "Sweetpea" is reportedly set to be handled by Foxconn, which has been preparing for mass production. According to The Decoder, Foxconn sees this as an opportunity to recover after losing all AirPods manufacturing contracts to Luxshare. Initially, OpenAI had favored Luxshare for production, but ultimately chose Foxconn to enable manufacturing outside of China.

Beyond "Sweetpea," Foxconn is also gearing up to produce other OpenAI devices, including a pen codenamed "Gumdrop," with plans to manufacture up to five different OpenAI products by 2028. This strategic partnership could mark a significant shift in the production dynamics of consumer electronics, particularly in the realm of AI-integrated devices.

In conclusion, if "Sweetpea" lives up to the expectations outlined in the leak, it could represent a formidable challenge to Apple's AirPods and set a new standard for AI-powered audio wearables. The integration of advanced AI technology and the involvement of a renowned designer suggest a product that could redefine the market. However, only time will tell whether OpenAI can successfully disrupt the established order in the wearables space.

This article is based on information provided by The Decoder.

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
OpenAI Develops 'Sweetpea' to Compete with Apple's AirPods Dominance in Wearables Market | Via News